CO5680403A2 - Antagonistas de mchr1r - Google Patents

Antagonistas de mchr1r

Info

Publication number
CO5680403A2
CO5680403A2 CO05007427A CO05007427A CO5680403A2 CO 5680403 A2 CO5680403 A2 CO 5680403A2 CO 05007427 A CO05007427 A CO 05007427A CO 05007427 A CO05007427 A CO 05007427A CO 5680403 A2 CO5680403 A2 CO 5680403A2
Authority
CO
Colombia
Prior art keywords
group
optionally substituted
alkyl
fluoro
linked
Prior art date
Application number
CO05007427A
Other languages
English (en)
Inventor
Emma Margareta Sigfridsson
Anna Stlna Maria Linusson
Pernilla Marie Sandberg
Inghardt Tord
Anette Marie Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5680403A2 publication Critical patent/CO5680403A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un compuesto de Fórmula (I)en donde R1 representa un grupo C1-4 alcoxi sustituido de manera opcional por uno o más fluoro o un grupo C1-4 alquilo sustituido de manera opcional por uno o más fluoro;n representa 0 ó 1;R2 representa un grupo C1-4 alquilo sustituido de manera opcional por uno o más fluoro o un grupo C1-4 alcoxi sustituido de manera opcional por uno o más fluoro;m representa 0 ó 1;R3 representa H ó un grupo C1-4 alquilo;L1 representa una cadena alquileno (CH2)r en la cual r representa 2 ó 3 ó L1 representa un grupo ciclohexilo en donde los dos nitrógenos que llevan R3 y R4, respectivamente, se enlazan al grupo ciclohexilo ya sea mediante las posiciones 1,3 ó 1,4 del grupo ciclohexilo ó L1 representa un grupo ciclopentilo en donde los dos nitrógenos que llevan R3 y R4, respectivamente, se enlazan al grupo ciclopentilo mediante la posición 1,3 del grupo ciclopentilo y, adicionalmente, cuando R5 representa 9,10-metanoantracen-9(10H)-ilo el grupo -L1-N(R4)- representa conjuntamente un anillo piperidilo que se enlaza a L2 a través del nitrógeno piperidinilo y a N-R3 mediante la posición 4 del anillo piperidilo con la condición de que cuando R5 representa 9, 10-metanoantracen-9(10H)-ilo, entonces r es únicamente 2;R4 representa H ó un grupo C1-4 alquilo sustituido de manera opcional por uno o más de los siguientes: un grupo arilo o un grupo heteroarilo; L2 representa un enlace o una cadena alquileno (CH2)s en la cual s representa 1, 2 ó 3, en donde la cadena alquileno se sustituye de manera opcional por uno o más de los siguientes: un grupo C1-4 alquilo, fenilo o heteroarilo;R5 representa arilo, un grupo heterocíclico o un grupo C3-8cicloalquilo que se fusiona de manera opcional a un fenilo o a un grupo heteroarilo;así como sus isómeros ópticos y racematos y sus sales farmacéuticamente aceptables; ...
CO05007427A 2002-07-08 2005-01-28 Antagonistas de mchr1r CO5680403A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
CO5680403A2 true CO5680403A2 (es) 2006-09-29

Family

ID=20288471

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05007427A CO5680403A2 (es) 2002-07-08 2005-01-28 Antagonistas de mchr1r

Country Status (19)

Country Link
US (1) US20060247439A1 (es)
EP (1) EP1528924A1 (es)
JP (1) JP2006501186A (es)
CN (1) CN1665502A (es)
AR (1) AR040476A1 (es)
AU (1) AU2003281194A1 (es)
BR (1) BR0312312A (es)
CA (1) CA2491835A1 (es)
CO (1) CO5680403A2 (es)
IL (1) IL165841A0 (es)
IS (1) IS7653A (es)
MX (1) MXPA05000336A (es)
NO (1) NO20045528L (es)
PL (1) PL374674A1 (es)
RU (1) RU2004138079A (es)
SE (1) SE0202134D0 (es)
TW (1) TW200412957A (es)
WO (1) WO2004004726A1 (es)
ZA (1) ZA200500030B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101475528A (zh) * 2003-03-31 2009-07-08 大正制药株式会社 新的喹啉、四氢喹唑啉和嘧啶衍生物以及与其应用有关的治疗方法
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
EP1706384A1 (en) * 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2005095357A2 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
JP2008514546A (ja) * 2004-09-30 2008-05-08 大正製薬株式会社 ピリジン誘導体及びその使用に関連する治療法
BRPI0519124A2 (pt) * 2004-12-17 2008-12-23 Lilly Co Eli composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
JP5111398B2 (ja) * 2006-01-25 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノシクロヘキサン類
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
JP5111509B2 (ja) 2006-09-28 2013-01-09 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ結合性を有するキノリン誘導体
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
US8710245B2 (en) 2009-12-04 2014-04-29 Psychogenics Inc. Multicyclic compounds and methods of use thereof
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
SG186275A1 (en) 2010-07-06 2013-01-30 Astrazeneca Ab Therapeutic agents 976
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CA3053903A1 (en) 2017-02-16 2018-08-23 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
WO2024062090A1 (en) 2022-09-23 2024-03-28 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
WO2024062089A1 (en) 2022-09-23 2024-03-28 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020283A (en) * 1958-10-20 1962-02-06 Abbott Lab Bis-lepidines
AU7997091A (en) * 1990-05-30 1991-12-31 American Home Products Corporation Substituted arylsulfonamides and benzamides
JP2001525793A (ja) * 1996-05-14 2001-12-11 ノボ ノルディスク アクティーゼルスカブ ソマトスタチンの作動因子及び拮抗因子
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT
TR200003170T2 (tr) * 1998-04-29 2001-01-22 Smithkline Beecham P.L.C. MRS inhibitörleri ve bakterisid olarak kullanılan quinolone'lar
JP4533534B2 (ja) * 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
EP1285651B1 (en) * 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
EP1359915A4 (en) * 2001-01-26 2004-07-21 Smithkline Beecham UROTENSIN-II RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
IL165841A0 (en) 2006-01-15
AR040476A1 (es) 2005-04-06
EP1528924A1 (en) 2005-05-11
ZA200500030B (en) 2005-11-11
NO20045528L (no) 2005-04-04
CN1665502A (zh) 2005-09-07
CA2491835A1 (en) 2004-01-15
WO2004004726A1 (en) 2004-01-15
SE0202134D0 (sv) 2002-07-08
AU2003281194A1 (en) 2004-01-23
RU2004138079A (ru) 2005-08-10
PL374674A1 (en) 2005-10-31
TW200412957A (en) 2004-08-01
MXPA05000336A (es) 2005-03-31
JP2006501186A (ja) 2006-01-12
IS7653A (is) 2005-01-19
BR0312312A (pt) 2005-04-12
US20060247439A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
CO5680403A2 (es) Antagonistas de mchr1r
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR033620A1 (es) Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO5611139A2 (es) Pirimidinas aril sustituidas y el uso de las mismas
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
AR035417A1 (es) Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
ECSP078064A (es) NUEVOS DERIVADOS de 2,4-DIANILINOPIRIMIDINAS, SU PREPARACIÓN, COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y PRINCIPALMENTE COMO INHIBIDORES DE IKK
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR048974A1 (es) Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas.
AR015512A1 (es) Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica
AR048959A1 (es) Amidas sustituidas del acido tiofencarboxilico; su obtencion y su uso como medicamentos con efecto antitrombotico.
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR039256A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
AR036634A1 (es) Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilen diamina sustituido por un radical silanico

Legal Events

Date Code Title Description
FA Application withdrawn